CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Audio By Carbonatix

BRISBANE, Calif.--(BUSINESS WIRE)--Oct 11, 2024--

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company’s newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares of CareDx common stock (“Option”), as an inducement material to entering into employment with CareDx, pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years in four equal annual installments beginning on October 8, 2025, the first anniversary of Ms. Huang’s employment commencement date, subject to her continued service through each vesting date. The Option has an exercise price of $32.16 and will vest over four years, with 25% of the total number of shares subject to the Option vesting on October 8, 2025, the first anniversary of Ms. Huang’s employment commencement date, and the remainder vesting at the end of each calendar month thereafter in equal installments, subject to her continued service through each vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the equity grants. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241011624732/en/

CONTACT: CareDx, Inc.

Media Relations

Anna Czene

818-731-2203

[email protected] Relations

Greg Chodaczek

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH SURGERY MEDICAL DEVICES HEALTH

SOURCE: CareDx, Inc.

Copyright Business Wire 2024.

PUB: 10/11/2024 04:30 PM/DISC: 10/11/2024 04:30 PM

http://www.businesswire.com/news/home/20241011624732/en